Macitentan · Opsumit

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Pulmonary arterial hypertension
Product first approved 2015firmenpresse.de
EU
  • Long-term treatment of pulmonary arterial hypertension (WHO FC II to III), adults and children
Product first approved 2013EMA
CA
  • OPSUMIT® (macitentan) is indicated for: • the long-term treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce morbidity in adult patients of WHO Functional Class II or III whose PAH is either idiopathic or heritable, or associated with connective tissue disease or congenital heart disease. • the long-term treatment of pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged 2 to less than 18 years of WHO Function Class II-III whose PAH is either idiopathic or heritable, or associated with connective tissue disease or congenital heart disease....
Product first approved 2013Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Pulmonary Arterial Hypertension
NCT04273945 · Actelion
2020-06-30 – 2029-02-20 · Pulmonary Arterial Hypertension
What this study did
NCT05167825 · Janssen Pharmaceutical K.K.
2022-11-14 – 2025-03-05 · Pulmonary Arterial Hypertension
What this study did
NCT03422328 · Actelion
2018-04-05 – 2023-12-27 · Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT02112487 · Actelion
2014-06-23 – 2018-09-19 · Pulmonary Arterial Hypertension
What this study did
NCT01739400 · Actelion
2013-09-10 – 2018-01-12 · Pulmonary Arterial Hypertension
What this study did
NCT01847014 · Actelion
2013-09-01 – 2017-11-30 · Pulmonary Arterial Hypertension
What this study did
NCT01743001 · Actelion
2013-05-21 – 2016-12-01 · Pulmonary Arterial Hypertension
What this study did
NCT02081690 · Actelion
2014-03-01 – 2015-11-01 · Pulmonary Arterial Hypertension
What this study did
NCT01841762 · Actelion
2013-04-01 – 2015-11-01 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT05179876 · Actelion
2022-05-04 – 2033-09-28 · Hypertension, Pulmonary
What this study did
NCT05946811 · University of Maryland, Baltimore
2024-05-01 – 2028-06-01 · Pulmonary Embolism
What this study did
NCT05140525 · Dr Sudarshan Rajagopal
2025-01-27 – 2026-05-01 · CTEPH
What this study did
NCT04271475 · Actelion
2020-07-07 – 2023-12-21 · Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT03775421 · Actelion
2019-04-11 – 2022-01-18 · Congenital Heart Disease With Fontan Circulation
What this study did
NCT03153137 · Actelion
2017-08-14 – 2021-07-26 · Congenital Heart Disease
What this study did
NCT03809650 · Actelion
2019-01-08 – 2020-06-29 · Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
What this study did
NCT01474122 · Actelion
2011-12 – 2014-02 · Digital Ulcers
What this study did
NCT01474109 · Actelion
2011-12 – 2013-11 · Systemic Sclerosis, Ulcers
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT04780932 · Assistance Publique - Hôpitaux de Paris
2021-06-14 – 2025-07-03 · Thromboembolic Pulmonary Hypertension, Chronic Disease, Inoperable Disease
What this study did
NCT03726398 · Franz Rischard, DO
2018-09-01 – 2020-08-03 · Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
What this study did
Phase 2 (10)
Pulmonary Arterial Hypertension
NCT03362047 · University of Giessen
2018-03-01 – 2024-08-14 · Pulmonary Arterial Hypertension (PAH)
What this study did
Other / comorbidity
NCT02060721 · Actelion
2015-02-03 – 2022-03-21 · Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT03714815 · Actelion
2018-12-07 – 2021-10-12 · Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
What this study did
NCT03153111 · Actelion
2017-07-11 – 2021-03-12 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT02554903 · Actelion
2016-03-28 – 2020-03-13 · Pulmonary Hypertension
What this study did
NCT02651272 · Boston University
2015-07 – 2019-12-18 · Pulmonary Hypertension, Sickle Cell Disease
What this study did
NCT02021292 · Actelion
2014-08-20 – 2016-09-28 · Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT01346930 · Actelion
2011-07-31 – 2016-08-31 · Idiopathic Pulmonary Fibrosis
What this study did
NCT00903331 · Actelion
2009-05 – 2011-08 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 1 (20)
Pulmonary Arterial Hypertension
NCT06553924 · Humanis Saglık Anonim Sirketi
2024-05-14 – 2024-08-08 · PAH
What this study did
NCT06553937 · Humanis Saglık Anonim Sirketi
2024-05-10 – 2024-07-31 · PAH
What this study did
Other / comorbidity
NCT07392281 · China-Japan Friendship Hospital
2025-09-01 – 2027-08-31 · Non-Coronary Obstructive Angina
What this study did
NCT06811831 · China-Japan Friendship Hospital
2024-11-01 – 2026-10-01 · Coronary Microvascular Angina, Macitentan
What this study did
NCT05731492 · Actelion
2024-03-14 – 2024-04-01 · Arterial Hypertension, Pulmonary
What this study did
NCT05433675 · Actelion
2022-06-22 – 2022-10-03 · Healthy
What this study did
NCT05392530 · Actelion
2022-05-25 – 2022-09-14 · Healthy
What this study did
NCT04963439 · Actelion
2021-07-08 – 2021-10-05 · Healthy
What this study did
NCT04540744 · Janssen Research & Development, LLC
2021-04-30 – 2021-08-30 · Healthy
What this study did
NCT04211272 · Actelion
2020-01-14 – 2021-04-19 · Healthy
What this study did
NCT04500808 · Janssen Pharmaceutical K.K.
2020-07-21 – 2020-12-14 · Healthy
What this study did
NCT04235270 · Janssen Research & Development, LLC
2020-01-17 – 2020-07-17 · Healthy
What this study did
NCT03389321 · Actelion
2018-01-09 – 2018-02-06 · Healthy Subjects
What this study did
NCT03359291 · Actelion
2017-11-03 – 2017-12-04 · Healthy Subjects
What this study did
NCT02254954 · Actelion
2015-01-08 – 2016-09-29 · Glioblastoma
What this study did
NCT02476864 · Actelion
2015-08 – 2015-12 · Healthy Subjects
What this study did
NCT02050802 · Actelion
2011-08 – 2011-11 · Healthy
What this study did
Phase 4 (6)
Pulmonary Arterial Hypertension
NCT02310672 · Actelion
2015-06-01 – 2019-09-10 · Pulmonary Arterial Hypertension
What this study did
NCT03236818 · Amsterdam UMC, location VUmc
2013-05 – 2017-09 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT05373108 · University of California, Los Angeles
2022-05-19 – 2023-02-14 · Cardiac Allograft Vasculopathy
What this study did
NCT02893176 · University of California, Los Angeles
2016-09 – 2019-09-19 · Lung Transplant Rejection
What this study did
NCT02382016 · Actelion
2015-06-23 – 2018-10-31 · Portopulmonary Hypertension
What this study did
Early phase / not applicable (1)
Pulmonary Arterial Hypertension
NCT03045666 · Soroka University Medical Center
2017-04-15 – 2018-05-01 · Pulmonary Arterial Hypertension
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Pulmonary Arterial Hypertension
NCT03904693 · Actelion
2019-07-29 – 2024-09-27 · Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Pulmonary Arterial Hypertension
NCT02558231 · Actelion
2016-05-01 – 2020-04-20 · Pulmonary Arterial Hypertension
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07844213 · China National Center for Cardiovascular Diseases
2022-08-25 – 2025-08-31 · Congenital Heart Disease, Pulmonary Hypertension
What this study did

Competitive landscape

Other Endothelin receptor (ETA/ETB, dual) drugs

Aprocitentan, Bosentan. Compare all 3 Endothelin receptor (ETA/ETB, dual) drugs

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Macitentan (Opsumit): this drugApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Aprocitentan (Tryvio)
Approved(overall)
Small moleculeEndothelin receptor (ETA/ETB, dual)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Opsumit (Macitentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Phase 3Hypertension, PulmonaryRecruiting
Est. primary completion 2027-01-31 · NCT05179876 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Non-Coronary Obstructive AnginaRecruiting
Est. primary completion 2027-08-31 · NCT07392281 · CT.gov ↗
What to watch

See the full readout calendar ↗